Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Coherus Bio (CHRS), 231% surge in interest
• Syros Pharmaceuticals (SYRS), 40% surge in interest
• Adma Biologics (ADMA), 24% surge in interest

Pipeline and key clinical candidates for these companies:

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of immunotherapies to treat cancer. Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer.

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.

ADMA Biologics describes itself as “an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.” ADMA currently manufactures and markets three FDA-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM for the treatment of primary humoral immunodeficiency; ASCENIV for the treatment of PI; and NABI-HB to provide enhanced immunity against the hepatitis B virus.

Recent news on these stocks:

January 22

Sandoz (SDZNY) has signed an agreement to acquire the U.S. biosimilar ranibizumab Cimerli from Coherus BioSciences for an upfront cash purchase payment of $170M. This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software. “Sandoz looks forward to providing even more treatment options for US patients with vision impairment and loss. The agreement to acquire the Cimerli business from Coherus allows us to build a more robust ophthalmic platform that would support future product launches. Closing is anticipated in 1H 2024, subject to standard conditions and approvals,” the company stated.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.